SAB Biotherapeutics (SABS) Interest & Investment Income (2021 - 2026)
SAB Biotherapeutics (SABS) reported Interest & Investment Income of $1.0 million for Q1 2026, up 1575.57% on a YoY basis from $62498.0 in Q1 2025, and up 49.44% quarter-over-quarter from $700739.0 in Q4 2025.
SAB Biotherapeutics (SABS) Interest & Investment Income (2021 - 2026) Analysis & Trends
SAB Biotherapeutics has reported Interest & Investment Income for 6 years, with the latest figure at $1.0 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income rose 1575.57% year-over-year to $1.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.4 million (up 184.12% YoY), and the FY2025 full-year result was $1.4 million, up 11.36% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $1.0 million, up from $700739.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $1.0 million in Q1 2026, with the low at $7933.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $260074.4 across 5 years, with a median of $62498.0 in 2025.
- Annual changes were most pronounced in 2024 — Interest & Investment Income soared 1829.64% — and 2025, when it plunged 96.38%.
- SAB Biotherapeutics' Interest & Investment Income stood at $29929.0 in 2022, then surged by 1517.31% to $484046.0 in 2023, then tumbled by 71.83% to $136374.0 in 2024, then soared by 413.84% to $700739.0 in 2025, then jumped by 49.44% to $1.0 million in 2026.
- The last three Interest & Investment Income figures came in at $1.0 million (Q1 2026), $700739.0 (Q4 2025), and $655233.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 597,319.59 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 305,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -14.79 Mn |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | 1.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.05 Mn |
| Dec 31, 2025 | 700,739.00 |
| Sep 30, 2025 | 655,233.00 |
| Jun 30, 2025 | 13,562.00 |
| Mar 31, 2025 | 62,498.00 |
| Dec 31, 2024 | 136,374.00 |
| Sep 30, 2024 | 277,174.00 |
| Jun 30, 2024 | 374,557.00 |
| Mar 31, 2024 | 497,893.00 |
| Dec 31, 2023 | 484,046.00 |
| Sep 30, 2023 | 14,364.00 |
| Jun 30, 2023 | 28,568.00 |
| Mar 31, 2023 | 57,988.00 |
| Dec 31, 2022 | 29,929.00 |
| Sep 30, 2022 | 17,385.00 |
| Jun 30, 2022 | 15,824.00 |
| Mar 31, 2022 | 7,933.00 |
| Dec 31, 2021 | 8,544.00 |
| Sep 30, 2021 | 3,769.00 |
| Jun 30, 2021 | 5,296.00 |